top of page
Browse by category
Search
FDA accepts Rhythm’s sNDA for setmelanotide in acquired hypothalamic obesity
The FDA has accepted for filing the Rhythm Pharmaceuticals’s supplemental New Drug Application (sNDA) for setmelanotide seeking approval...
Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome
Researchers from the George Washington University have uncovered evidence in an animal study that shows setmelanotide, an FDA-approved...
TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in patients with acquired hypothalamic obesity
Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a...
Neurons that control the amount of MC4R affect how much the protein guards against obesity
Mutations in a gene called OTP cause obesity by controlling the output of another gene already targeted by an anti-obesity drug, a study...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The European Medicines Agency (EMA) has issued a positive opinion on the Rhythm Pharmaceuticals’ orphan drug designation request for...
Browse by tag
bottom of page